MDRX:NGS-Allscripts Healthcare Solutions Inc. (USD)

EQUITY | Health Information Services | Nasdaq Global Select

Last Closing

USD 7.96

Change

0.00 (0.00)%

Market Cap

USD 2.05B

Volume

0.25M

Analyst Target

USD 9.97
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Allscripts Healthcare Solutions Inc is a provider of clinical, financial, connectivity and information solutions and related professional services that empower hospitals, physicians and post-acute organizations to deliver world-class outcomes.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-27 )

Largest Industry Peers for Health Information Services

Symbol Name Price(Change) Market Cap
MTHRF M3 Inc

N/A

USD 7.92B
MTHRY M3 Inc

N/A

USD 7.86B
PMCUF Pro Medicus Limited

N/A

USD 7.45B
CMPVF CompuGroup Medical SE & Co. KG..

N/A

USD 1.56B
SMSZF SMS Co. Ltd

N/A

USD 1.55B
PANHF Ping An Healthcare and Technol..

N/A

USD 1.50B
CRWRF Craneware plc

N/A

USD 1.01B
SUSRF Surgical Science Sweden AB (pu..

N/A

USD 0.71B
RSLBF RaySearch Laboratories AB (pub..

N/A

USD 0.38B
KSIOF kneat.com inc.

N/A

USD 0.25B

ETFs Containing MDRX

C9DF:XETRA Frankfurter UCITS-ETF - M.. 4.40 % 0.00 %

N/A

N/A
SXRJ:F iShares VII Public Limite.. 0.97 % 0.00 %

N/A

USD 0.82B
SXRJ:XETRA iShares MSCI EMU Small Ca.. 0.97 % 0.00 %

N/A

USD 0.77B
CSEMUS:SW iShares VII PLC - iShares.. 0.97 % 0.00 %

N/A

USD 0.82B
UEFD:F UBS (Lux) Fund Solutions .. 0.97 % 0.00 %

N/A

USD 0.21B
UEFD:XETRA UBS(Lux)Fund Solutions .. 0.97 % 0.00 %

N/A

USD 0.15B
ESCEUA:SW UBS(Lux)Fund Solutions .. 0.97 % 0.00 %

N/A

USD 0.21B
MMS:PA Amundi MSCI EMU Small Cap.. 0.91 % 0.00 %

N/A

USD 0.33B
LGWU:F Lyxor Index Fund - Lyxor .. 0.91 % 0.00 %

N/A

USD 0.29B
LGWU:XETRA Amundi MSCI EMU Small Cap.. 0.91 % 0.00 %

N/A

USD 0.27B
ZPRX:F SSgA SPDR ETFs Europe II .. 0.71 % 0.00 %

N/A

USD 0.19B
ZPRX:XETRA SPDR® MSCI Europe Small .. 0.71 % 0.00 %

N/A

USD 0.17B
XXSC:LSE db x-trackers MSCI Europe.. 0.51 % 0.00 %

N/A

USD 1.51B

Market Performance

  Market Performance vs. Industry/Classification (Health Information Services) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -24.12% 35% F 21% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -24.12% 32% F 21% F
Trailing 12 Months  
Capital Gain -36.27% 53% F 32% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -36.27% 53% F 31% F
Trailing 5 Years  
Capital Gain -19.35% 82% B 56% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -19.35% 79% B- 51% F
Average Annual (5 Year Horizon)  
Capital Gain 16.14% 70% C- 63% D
Dividend Return 16.14% 69% C- 59% D-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 59.67% 50% F 44% F
Risk Adjusted Return 27.04% 80% B- 62% D
Market Capitalization 2.05B 92% A 69% C-

Key Financial Ratios

  Ratio vs. Industry/Classification (Health Information Services) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 9.26 72% 63%
Price/Book Ratio 0.70 86% 73%
Price / Cash Flow Ratio N/A N/A N/A
Price/Free Cash Flow Ratio 1.85 14% 31%
Management Effectiveness  
Return on Equity 8.93% 87% 67%
Return on Invested Capital 18.08% 63% 80%
Return on Assets 2.16% 85% 67%
Debt to Equity Ratio N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.